For Republic of Ireland healthcare
professionals only

For primary prevention of venous thromboembolic events (VTE) in adult patients who have
undergone elective total hip or knee replacement surgery^1,2

• Home page
• Stroke prevention in AF
• DVT/PE treatment & secondary prevention
• Contact
• Adverse events
• SPCs

Primary prevention of venous thromboembolism (pVTE)

For primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip or knee replacement surgery^1,2

1. Educational Pack

An educational pack has been developed to support the prescribing of Pradaxa^® for primary prevention of VTE. It provides practical and relevant information about the appropriate use of Pradaxa^®.

The pack contains:

• Prescriber guide
• Summaries of Product Characteristics (SPCs)
• Patient alert card

Pradaxa^® (dabigatran etexilate) – Patient Alert Card to be included in Pradaxa^® packs

Starting from December 2014, the Pradaxa^® Patient Alert Card will be provided in packs of Pradaxa^® capsules as a package insert. The Pradaxa^® Patient Alert Card is intended to be carried by patients taking Pradaxa^®, and provides information to both patients and healthcare professionals regarding the safe use of Pradaxa^®.

References:

1. Boehringer Ingelheim. Pradaxa^® 110mg hard capsules Summary of Product Characteristics.
2. Boehringer Ingelheim. Pradaxa^® 75mg hard capsules Summary of Product Characteristics.

© 2016 Boehringer Ingelheim Ireland Ltd. All rights reserved.

↑ Back to top

• Adverse events
• Prescribing information
• SPCs
• Terms of use

IRE/DBG-151194(2) Date of preparation: August 2017